Capricor Therapeutics (NASDAQ:CAPR) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report released on Sunday morning.

A number of other equities research analysts also recently issued reports on CAPR. UBS Group set a $50.00 price target on shares of Capricor Therapeutics in a research report on Monday, December 15th. Industrial Alliance Securities set a $48.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Oppenheimer upped their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright boosted their price target on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $40.82.

Capricor Therapeutics Trading Down 6.7%

Capricor Therapeutics stock opened at $23.84 on Friday. The stock has a fifty day moving average price of $17.95 and a 200 day moving average price of $11.07. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The firm has a market capitalization of $1.09 billion, a P/E ratio of -13.24 and a beta of 0.22.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). As a group, equities analysts predict that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. GoalVest Advisory LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $59,000. PVG Asset Management Corp purchased a new position in Capricor Therapeutics in the 3rd quarter worth approximately $91,000. Voleon Capital Management LP acquired a new stake in Capricor Therapeutics in the third quarter valued at approximately $311,000. Moneta Group Investment Advisors LLC grew its position in Capricor Therapeutics by 25.5% in the third quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $123,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.